TABLE 2.
Ferret neutralization titers on day 42 post-prime sera (day 14 post-boost)a
| Preimmunity | Vaccine | Significance group | Chk/pots/84 | Chk/PA/04 | For/57 | T/64 | Duk/HK/78 | Sw/MO/06 | Mall/MN/08 |
|---|---|---|---|---|---|---|---|---|---|
| H2N2 | Mal/NL/01 | a | 640 | 380 | 48 | 34 | 640 | 640 | 452 |
| H2N2 | Mal/WI/08 | a | 640 | 537 | 48 | 56 | 640 | 640 | 640 |
| H2N2 | Z1 | a | 640 | 640 | 134 | 67 | 640 | 640 | 640 |
| H2N2 | Z5 | a | 452 | 640 | 40 | 380 | 537 | 640 | 320 |
| H2N2 | Mock | b | 95 | 156 | 8 | 24 | 48 | 537 | 95 |
| H3N2 | Mal/NL/01 | b | 17 | 7 | 5 | 20 | 12 | 452 | 17 |
| H3N2 | Mal/WI/08 | ab | 48 | 67 | 5 | 28 | 24 | 640 | 67 |
| H3N2 | Z1 | a | 190 | 56 | 7 | 40 | 67 | 640 | 95 |
| H3N2 | Z5 | ab | 113 | 113 | 5 | 20 | 34 | 640 | 48 |
| H3N2 | Mock | c | 5 | 7 | 5 | 5 | 5 | 6 | 6 |
| H1N1 | Mal/NL/01 | b | 113 | 20 | 5 | 95 | 28 | 537 | 24 |
| H1N1 | Mal/WI/08 | ab | 113 | 40 | 6 | 537 | 34 | 640 | 226 |
| H1N1 | Z1 | a | 537 | 269 | 20 | 80 | 269 | 640 | 269 |
| H1N1 | Z5 | ab | 134 | 48 | 10 | 20 | 80 | 640 | 12 |
| H1N1 | Mock | c | 8 | 6 | 5 | 5 | 5 | 5 | 5 |
| H3N2, H1N1 | Mal/NL/01 | ac | 269 | 160 | 28 | 34 | 95 | 640 | 134 |
| H3N2, H1N1 | Mal/WI/08 | a | 113 | 113 | 10 | 34 | 67 | 640 | 134 |
| H3N2, H1N1 | Z1 | c | 640 | 380 | 28 | 160 | 537 | 640 | 226 |
| H3N2, H1N1 | Z5 | ac | 226 | 160 | 17 | 48 | 160 | 640 | 160 |
| H3N2, H1N1 | Mock | b | 5 | 5 | 7 | 5 | 5 | 6 | 6 |
| H1N1, H3N2 | Mal/NL/01 | a | 640 | 640 | 34 | 5 | 80 | 640 | 640 |
| H1N1, H3N2 | Mal/WI/08 | a | 537 | 269 | 40 | 40 | 80 | 640 | 380 |
| H1N1, H3N2 | Z1 | a | 226 | 640 | 67 | 113 | 95 | 640 | 537 |
| H1N1, H3N2 | Z5 | a | 269 | 269 | 20 | 40 | 113 | 640 | 190 |
| H1N1, H3N2 | Mock | b | 5 | 6 | 5 | 5 | 5 | 5 | 5 |
| Mock | Mal/NL/01 | b | 34 | 14 | 5 | 10 | 10 | 640 | 20 |
| Mock | Mal/WI/08 | ab | 12 | 17 | 5 | 5 | 7 | 640 | 20 |
| Mock | Z1 | c | 537 | 190 | 40 | 80 | 226 | 640 | 80 |
| Mock | Z5 | b | 160 | 28 | 6 | 10 | 56 | 380 | 14 |
| Mock | Mock | a | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Neutralization titers were obtained from pooled sera. Titers were obtained by taking the geometric mean titer of the replicates for each of the vaccine groups. Each column is a virus that was used in the neutralization assay. Each row is the sera from a vaccination group. The lower limit of detection is 5, while the upper limit of detection is 640. Significance group is determined for each individual preimmunity group. Within one preimmune group, the vaccines’ ability to elicit neutralization titers were compared while controlling for the main effects of virus used in the assay. Vaccination groups within a preimmunity that share a lowercase letter were not significantly different from one another.